Aminu Kano Teaching Hospital

Running trials

• Recruiting

  Intensive Combination Approach to Rollback the HIV Epidemic in Nigerian Youth (iCARE) Plus Effectiveness/Implementation Hybrid Study

  NCT06880224· Northwestern University· Source

• Recruiting

  A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

  NCT06609226· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Improving Maternal Cardiovascular Outcomes Through the Implementation of a Hypertensive Disorders of Pregnancy Bundle in Nigeria

  NCT06859359· Washington University School of Medicine· Source

• Recruiting

  Stroke Prevention in Nigeria 2 Trial

  NCT06526117· Phase 4· Vanderbilt University Medical Center· Source

• Recruiting

  Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)

  NCT05580666· Phase 3· Population Health Research Institute· Source

• Active, not recruiting

  Stroke Prevention in Young Adults With Sickle Cell Anemia

  NCT04808778· Vanderbilt University Medical Center· Source

• Active, not recruiting

  A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

  NCT04624659· Phase 3· Forma Therapeutics, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• HIV2 recruiting
• Sickle cell disease2 recruiting
• High blood pressure1 recruiting
• Stroke1 recruiting
• Thalassaemia1 recruiting

Closed trials

• Terminated

  GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

  NCT05632354· Phase 2/3· Pfizer· Source

• Recruiting

  A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

  NCT05431088· Phase 2/3· Pfizer· Source

• Completed

  Screening for Pregnancy Related Heart Failure in Nigeria

  NCT05438576· Mayo Clinic· Source

• Terminated

  Resolution of Sickle Cell Leg Ulcers With Voxelotor

  NCT05561140· Phase 3· Pfizer· Source

• Completed

  A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study

  NCT05142254· Phase 2· Vanderbilt University Medical Center· Source

• Terminated

  A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

  NCT05348915· Phase 3· Pfizer· Source

• Terminated

  A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

  NCT04927247· Phase 3· Pfizer· Source

• Completed

  A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

  NCT04935879· Phase 3· Pfizer· Source

• Terminated

  Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria

  NCT03201939· Phase 2· Vanderbilt University Medical Center· Source

• Terminated

  Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

  NCT04218084· Phase 3· Pfizer· Source

• Completed

  Bridging the Childhood Epilepsy Treatment Gap in Africa

  NCT04290975· Vanderbilt University Medical Center· Source

• Completed

  The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria

  NCT04800809· Vanderbilt University Medical Center· Source

• Terminated

  Open-Label Extension of Voxelotor

  NCT04188509· Phase 3· Pfizer· Source